Role of capsule endoscopy in inflammatory bowel disease

Table 3 Key studies describing the role of videocapsule endoscopy in established Crohn’s disease

Indication	Ref.	n	Inclusion criteria	Diagnostic criteria	Results
Mucosal healing	Efthimyou et al[28]	40	Patients with active CD (CDAI > 150) who responded to anti-inflammatory treatment, VCE was performed before and after treatment	Number of aphthous ulcers/large ulcers/length of involved segment	Only number of large ulcers correlated with response (8.3 ± 1.4 and 5/0.8, 95%CI: 0.8-5.9, P < 0.01)
Postoperative recurrence	Bourreille et al[31]	31	CD with ileocolonic anastomosis	Rutgeerts score ≥ 1	VCE-21/31 (68%), IC-19/31 (61%)
	Pons Beltrán et al[32]	24	CD with ileocolonic anastomosis	Rutgeerts score ≥ 2	VCE-14/22 (55%), IC-6/24 (25%)
Unexplained symptoms	Dubcenco et al[34]	28	Active CD patients	≥ 3 ulcers	VCE-23 (82%), IC-14 50%, barium radiography-9 (32%)
	Dussault et al[35]	25	Active CD patients with unexplained symptoms	Severity graded by number and appearance of ulcers and presence of stenosis	Active SB inflammation: 11/25 (44%)

In 6 patients treated with immunomodulators, biologics or corticosteroids, a significant improvement was demonstrated in all 3 parameters. CD: Crohn’s disease; VCE: Vidoecapsule endoscopy; IC: Ileocolonoscopy; SB: Small bowel.